New Horizons for EPP, Erythropoietic Protoporphyria: Advances in Access to Therapies.
The Erythropoietic Protoporphyria (EPP) patient community is celebrating significant news regarding access to treatments.
Recently, Canada marked a major milestone with the approval of SCENESSE® (afamelanotide) by Health Canada, an agency that has granted a Notice of Compliance (NOC) for the prevention of phototoxicity in adult patients with EPP.
This authorization, which joins the approvals already obtained in Europe, the United States, and Australia, formalizes the path for Canadian patients to access this therapy through specialized centers, ensuring an internationally recognized standard of care. Meanwhile, in Latin America, the landscape is also moving toward greater equity and access to medication. With the firm purpose of narrowing access gaps, CLINUVEL has forged a strategic partnership with Valentech Pharma, experts in rare diseases, to introduce this therapy to the region. This collaboration not only seeks to implement special access programs and regulatory pathways but also arrives at a key moment when various Latin American countries are strengthening their legislation to guarantee support for medications aimed at patients with severe conditions.
An Innovative Approach to Photoprotection
SCENESSE® has established itself as the world's first and only systemic photoprotective therapy approved for the treatment of EPP. The drug contains afamelanotide, a synthetic form of the hormone alpha-melanocyte-stimulating hormone (α-MSH), which works in close harmony with the patient's biology.
By stimulating the production of eumelanin—the body’s natural dark pigment—the medication acts as a potent antioxidant and creates a shield that prevents light penetration. For those living with EPP, whose lives are limited by debilitating phototoxic reactions and intense pain upon the slightest exposure to visible or sunlight, this mechanism of action means much more than a treatment: it is the possibility of recovering a quality of life that was previously unimaginable, supported by a safety profile consolidated over two decades of clinical use.
